CytoReason Team (Facebook)
Cytoreason, an Israeli medtech startup, raised $20 million from Pfizer in an extension of its multi-year partnership with that company to use CytoReason’s artificial intelligence technology for Pfizer’s drug development programs. The new funds will be an equity investment and Pfizer will have options to license CytoReason’s platform and disease models, and fund supplementary project support, in a deal potentially worth up to $110M over the next five years.
Since launching the collaboration in 2019, Pfizer has used CytoReason’s biological models in its research to enhance the understanding of the immune system, as it develops innovative drugs for immune-mediated and immuno-oncology diseases. CytoReason’s platform has provided Pfizer with multiple insights in research and development programs across over 20 diseases.
Founded in 2016, CytoReason is a tech company developing a computational model of the human body. The company collects proprietary data from pharma companies and uses it to simulate human diseases – tissue by tissue, cell by cell. With CytoReason’s database and AI-led platform, pharma and biotech companies identify new opportunities, shorten trial phases, reduce development costs and increase the likelihood of drug approval. To date, five of the world’s top ten pharma companies use CytoReason’s technology.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
The new research agreement and investment will support the development of additional disease models and the creation of high-resolution models, spanning across a number of therapeutic areas.
David Harel, CEO and Co-founder of CytoReason said, “Pfizer has been a strategic partner of CytoReason since 2019, and we are thrilled to scale our collaboration as one of Pfizer’s trusted AI partners for accelerating drug development. This partnership is advancing a significant shift in the biotech industry, and helping drive future R&D for pharmaceutical companies as they continue to use machine learning to develop treatments more efficiently. Transforming complex data into useful actionable insights will potentially provide leading researchers and scientists a roadmap to further develop their drug portfolios.”
